Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Mezger

Showing results (51-60 of 64) with videos related to

Pageof 7
Sort By:
Zeitschrift Fur Gastroenterologie|October 1, 1996
[Libyan patient with chronic diarrhea]J Mezger, P Malfertheiner, A Glasmacher, et al.
Deutsche Medizinische Wochenschrift (1946)|February 8, 1991
[Carcinoembryonic antigen in serum and pleural fluid to distinguish between bronchial carcinoma and pleural mesothelioma]J Mezger, R Lamerz, M Bresgen, et al.
Lung|January 1, 1994
Value of serum and effusion fluid CEA levels for distinguishing between diffuse malignant mesothelioma and carcinomatous pleural metastasesJ Mezger, A Calavrezos, P Drings, et al.
The European Respiratory Journal|February 17, 2006
Efficacy of a toxicity-adjusted topotecan therapy in recurrent small cell lung cancerR M Huber, M Reck, H Gosse, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2003
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetronR Gralla, M Lichinitser, S Van Der Vegt, et al.
Leukemia|January 22, 1998
Oral idarubicin, dexamethasone and vincristine (VID) in the treatment of multiple myelomaA Glasmacher, T Haferlach, M Gorschlüter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 13, 2010
Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)M Reck, J von Pawel, P Zatloukal, et al.
Leukemia|September 16, 1998
Antifungal prophylaxis with itraconazole in neutropenic patients with acute leukaemiaA Glasmacher, E Molitor, C Hahn, et al.
Zeitschrift Fur Gastroenterologie|February 9, 2005
Population-based registration of unselected colorectal cancer patients: five-year survival in the region of Bonn/Rhine-Sieg, GermanyC Lamberti, K Di Blasi, D Archut, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 10, 1997
Comparison of three tropisetron-containing antiemetic regimens in the prophylaxis of acute and delayed chemotherapy-induced emesis and nauseaS Drechsler, U Bruntsch, J Eggert, et al.
Pageof 7

Showing results (51-60 of 64) with videos related to

Sort By:
Pageof 7
Zeitschrift Fur Gastroenterologie|October 1, 1996
[Libyan patient with chronic diarrhea]J Mezger, P Malfertheiner, A Glasmacher, et al.
Deutsche Medizinische Wochenschrift (1946)|February 8, 1991
[Carcinoembryonic antigen in serum and pleural fluid to distinguish between bronchial carcinoma and pleural mesothelioma]J Mezger, R Lamerz, M Bresgen, et al.
Lung|January 1, 1994
Value of serum and effusion fluid CEA levels for distinguishing between diffuse malignant mesothelioma and carcinomatous pleural metastasesJ Mezger, A Calavrezos, P Drings, et al.
The European Respiratory Journal|February 17, 2006
Efficacy of a toxicity-adjusted topotecan therapy in recurrent small cell lung cancerR M Huber, M Reck, H Gosse, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2003
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetronR Gralla, M Lichinitser, S Van Der Vegt, et al.
Leukemia|January 22, 1998
Oral idarubicin, dexamethasone and vincristine (VID) in the treatment of multiple myelomaA Glasmacher, T Haferlach, M Gorschlüter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 13, 2010
Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)M Reck, J von Pawel, P Zatloukal, et al.
Leukemia|September 16, 1998
Antifungal prophylaxis with itraconazole in neutropenic patients with acute leukaemiaA Glasmacher, E Molitor, C Hahn, et al.
Zeitschrift Fur Gastroenterologie|February 9, 2005
Population-based registration of unselected colorectal cancer patients: five-year survival in the region of Bonn/Rhine-Sieg, GermanyC Lamberti, K Di Blasi, D Archut, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 10, 1997
Comparison of three tropisetron-containing antiemetic regimens in the prophylaxis of acute and delayed chemotherapy-induced emesis and nauseaS Drechsler, U Bruntsch, J Eggert, et al.
Pageof 7